Inflammatory biomarkers, race/ethnicity and cardiovascular disease

Area of Science:

• Public Health
• Cardiology
• Health Disparities

Background:

• Cardiovascular disease (CVD) is a leading cause of death in developed nations, with significant costs.
• Racial and ethnic disparities in CVD morbidity and mortality are evident in the US, with African Americans experiencing the highest death rates.
• Current CVD risk reduction strategies, like hyperlipidemia screening, are insufficient for identifying all high-risk individuals.

Purpose of the Study:

• To highlight the need for research into the multifactorial basis of racial/ethnic disparities in CVD.
• To emphasize the importance of inflammation and thrombosis markers in CVD risk assessment across diverse populations.
• To identify and address barriers hindering ethnic minority participation in cardiovascular research.

Main Methods:

• Review of existing literature on CVD, racial/ethnic disparities, and risk markers.
• Analysis of data on hyperlipidemia screening effectiveness and limitations.
• Identification of barriers to research participation for ethnic minority groups.

Main Results:

• Hyperlipidemia treatment, while effective, does not identify all individuals at high CVD risk.
• Inflammation and thrombosis markers (e.g., hs-CRP, homocysteine) are associated with CVD risk, but data across racial/ethnic groups are limited.
• Significant barriers impede the inclusion of ethnic minorities in US-based research studies.

Conclusions:

• Addressing racial/ethnic disparities in CVD requires a deeper understanding of underlying biological and social factors.
• Further research is crucial to validate CVD risk markers across diverse populations.
• Overcoming barriers to research participation is essential for achieving health equity in cardiovascular disease prevention and treatment.